白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
Journal of Leukemia & Lymphoma
2015年
9期
573-576
,共4页
费城染色体样急性淋巴细胞白血病%基因%治疗%预后
費城染色體樣急性淋巴細胞白血病%基因%治療%預後
비성염색체양급성림파세포백혈병%기인%치료%예후
Ph-like acute lymphoblastic leukemia%Genome%Therapy%Prognosis
费城染色体样急性淋巴细胞白血病(Ph-like ALL)涉及与其高危特点和预后不良相关的多种基因组改变,如IKZF1 、CRLF2、JAK1/2、EBF1-PDGFRB、ATF7IP、EPOR、SH2B3等.JAK/STAT途径和PI3K/mTOR途径已被证实很可能是某些Ph-like ALL的相关靶点,文章重点综述以上基因组改变及治疗进展.
費城染色體樣急性淋巴細胞白血病(Ph-like ALL)涉及與其高危特點和預後不良相關的多種基因組改變,如IKZF1 、CRLF2、JAK1/2、EBF1-PDGFRB、ATF7IP、EPOR、SH2B3等.JAK/STAT途徑和PI3K/mTOR途徑已被證實很可能是某些Ph-like ALL的相關靶點,文章重點綜述以上基因組改變及治療進展.
비성염색체양급성림파세포백혈병(Ph-like ALL)섭급여기고위특점화예후불량상관적다충기인조개변,여IKZF1 、CRLF2、JAK1/2、EBF1-PDGFRB、ATF7IP、EPOR、SH2B3등.JAK/STAT도경화PI3K/mTOR도경이피증실흔가능시모사Ph-like ALL적상관파점,문장중점종술이상기인조개변급치료진전.
Ph-like acute lymphoblastic leukemia (Ph-like ALL) involves various genomic alterations associated with high risk factors and poor clinical outcome, such as IKZF1, CRLF2, JAK1/2, EBF1-PDGFRB, ATF7IP, EPOR, SH2B3.JAK/STAT pathway and PI3K/mTOR pathway are likely to be the targets of Ph-like ALL.Here,the above genomic alterations and treatment progress are reviewed.
